Frits van Rhee

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi request reprint Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA Electronic address
    Lancet Oncol 15:966-74. 2014
  2. pmc Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels
    Katie Stone
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 8:e54610. 2013
  3. pmc Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
    Tarun K Garg
    Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 4301 West Markham, Little Rock, AR 72205 USA
    Haematologica 97:1348-56. 2012
  4. ncbi request reprint Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 8:486-98. 2010
  5. pmc NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301 West Markham, no 776, Little Rock, AR 72205, USA
    Blood 105:3939-44. 2005
  6. ncbi request reprint Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 28:3701-8. 2010
  7. pmc Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009
  8. ncbi request reprint Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Nat Clin Pract Oncol 5:70-1. 2008
  9. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
  10. pmc High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:1754-64. 2008

Research Grants

Collaborators

Detail Information

Publications72

  1. ncbi request reprint Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA Electronic address
    Lancet Oncol 15:966-74. 2014
    ..We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease...
  2. pmc Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels
    Katie Stone
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 8:e54610. 2013
    ..These data suggest that interleukin-6 receptor polymorphism may be a contributing factor in Castleman Disease, and further research is warranted...
  3. pmc Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
    Tarun K Garg
    Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 4301 West Markham, Little Rock, AR 72205 USA
    Haematologica 97:1348-56. 2012
    ....
  4. ncbi request reprint Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 8:486-98. 2010
    ..Important strides forward have also been made in the management of HIV-positive CD...
  5. pmc NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301 West Markham, no 776, Little Rock, AR 72205, USA
    Blood 105:3939-44. 2005
    ..The pool of NY-ESO-1-specific cytotoxic T cells expands easily on NY-ESO-1 peptide stimulation and is functionally active. NY-ESO-1 should therefore be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM...
  6. ncbi request reprint Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 28:3701-8. 2010
    ..Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD...
  7. pmc Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009
    ....
  8. ncbi request reprint Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Nat Clin Pract Oncol 5:70-1. 2008
  9. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
    ..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients...
  10. pmc High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:1754-64. 2008
    ..In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989...
  11. ncbi request reprint Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    N Engl J Med 354:1021-30. 2006
    ..High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival...
  12. ncbi request reprint Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 136:393-9. 2007
    ..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM...
  13. pmc Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
    Bijay Nair
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 115:4168-73. 2010
    ..The robustness of the GEP risk model should be exploited in clinical trials aimed at improving the notoriously poor outcome in high-risk disease...
  14. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
    ..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy...
  15. pmc Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 121:1819-23. 2013
    ..This trial was registered at www.clinicaltrials.gov as #NCT00081939 and # NCT00572169...
  16. pmc Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
    Bijay Nair
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Blood 113:6572-5. 2009
    ..001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma...
  17. pmc Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 140:625-34. 2008
    ..Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose-density in TT3 vs. TT2...
  18. pmc International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols
    Sarah Waheed
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 117:1001-9. 2011
    ....
  19. pmc Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 109:1692-700. 2007
    ..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias...
  20. pmc Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 116:1220-7. 2010
    ....
  21. pmc Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3122-5. 2008
    ..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382...
  22. pmc Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile
    Yiming Zhou
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham 816, Little Rock, AR 72205, USA
    Br J Haematol 145:637-41. 2009
    ..42, P = 0.004). The prevalence of high-risk myeloma in the RS+/FL+ group may reflect a dissemination-prone condition not shared by the other three groups...
  23. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
    ..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
  24. doi request reprint NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
    Sathisha Upparahalli Venkateshaiah
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Exp Hematol 41:547-557.e2. 2013
    ..These findings indicate that MM cells and osteoclasts are highly sensitive to NAD(+) depletion and that PBEF1 inhibition represents a novel approach to target cellular metabolism and inhibit PARP-1 and bone disease in MM...
  25. pmc Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Blood 121:4753-7. 2013
    ..Thus, treatment, host, and myeloma features could be linked to MDS development after therapy for this malignancy. This trial was registered at www.clinicaltrials.gov: TT3A: NCT00081939, TT3B: NCT00572169...
  26. pmc Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3115-21. 2008
    ..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well...
  27. ncbi request reprint Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
    Bart Barlogie
    Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 107:2633-8. 2006
    ..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma...
  28. pmc Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 141:433-44. 2008
    ..These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design...
  29. pmc The Arkansas approach to therapy of patients with multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
    Best Pract Res Clin Haematol 20:761-81. 2007
    ....
  30. pmc TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 147:347-51. 2009
    ..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent...
  31. pmc High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
    Yiming Zhou
    Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Proc Natl Acad Sci U S A 107:7904-9. 2010
    ..Silencing of AGO2 dramatically decreased viability in MM cell lines. Genome-wide elevated expression of miRNAs in high-risk MM may be secondary to deregulation of AGO2 and the enzyme complexes that regulate miRNA maturation and function...
  32. pmc Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
    Xenofon Papanikolaou
    Myeloma Institute for Research and Therapy, Little Rock, AR, USA
    Haematologica 98:1147-53. 2013
    ..In conclusion, metronomic therapy is an effective late salvage treatment in relapsed/refractory multiple myeloma, with a high overall response rate and a favorable toxicity profile...
  33. ncbi request reprint A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
    ..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions...
  34. ncbi request reprint Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:2720-5. 2008
    ..Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance...
  35. ncbi request reprint Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 137:530-6. 2007
    ....
  36. pmc Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 28:3023-7. 2010
    ..After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization...
  37. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
    ..001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)...
  38. ncbi request reprint Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma Myeloma 6:469-74. 2006
    ..Complete response has been considered a surrogate for favorable long-term outcome in multiple myeloma. Data on the impact of the duration of response on prognosis are lacking...
  39. pmc Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
    Blood 118:3512-24. 2011
    ..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels...
  40. pmc Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
    Blood 111:94-100. 2008
    ..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted...
  41. ncbi request reprint Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications
    Ronald Walker
    Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 25:1121-8. 2007
    ..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)...
  42. ncbi request reprint Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  43. pmc Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
    Christoph J Heuck
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Clin Cancer Res 18:5499-506. 2012
    ....
  44. pmc Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
    Jumei Shi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 143:641-53. 2008
    ..Encouragingly, 50% of patients achieved (near) complete remission. These data set the stage for future studies of KIR-ligand mismatched NK cell therapy in the autologous setting...
  45. pmc F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
    Twyla B Bartel
    Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:2068-76. 2009
    ..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy...
  46. ncbi request reprint Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma
    Susann Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Immunother 30:847-54. 2007
    ..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM...
  47. pmc First thalidomide clinical trial in multiple myeloma: a decade
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:1035-8. 2008
    ..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma...
  48. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
    ..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...
  49. pmc Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 120:1597-600. 2012
    ..38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B)...
  50. pmc Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
    Jumei Shi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 111:1309-17. 2008
    ..Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells...
  51. pmc Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
    Sarah Waheed
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Haematologica 98:71-8. 2013
    ..Clinicaltrials.gov identifier: NCT00081939)...
  52. pmc Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
    Rakesh Bam
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Hematol 88:463-71. 2013
    ..These data demonstrate BTK and cell-surface CXCR4 association in myeloma cells and that BTK plays a role in myeloma cell homing to bone and myeloma-induced bone disease. Am. J. Hematol. 88:463-471, 2013. © 2013 Wiley Periodicals, Inc...
  53. pmc Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
    Amberly Moreno-Bost
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cytotherapy 13:618-28. 2011
    ....
  54. ncbi request reprint Con: allogeneic transplantation in multiple myeloma
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 4:391-4. 2006
  55. pmc Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatio
    Ichiro Hanamura
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St 776, Little Rock, AR 72205, USA
    Blood 108:1724-32. 2006
    ..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis...
  56. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    ..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
  57. ncbi request reprint Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma
    Ramesh B Batchu
    Myeloma Institute for Research and Therapy, Section for Gene and Immunotherapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer Res 65:10041-9. 2005
    ..Thus, PTD-NY-ESO-1 accesses the cytoplasm by protein transduction, is processed by the proteasome, and NY-ESO-1 peptides presented by HLA class I elicit NY-ESO-1-specific T lymphocytes...
  58. pmc Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, 816, Little Rock, AR 72205
    J Clin Oncol 28:1209-14. 2010
    ....
  59. pmc Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma
    Bo Hu
    Myeloma Institute for Research and Therapy, Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 8:e74191. 2013
    ..These results provide a novel molecular mechanism critical to understanding the anabolic role of carfilzomib on myeloma-induced bone disease. ..
  60. pmc In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes
    Erming Tian
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR, 72205
    Genes Chromosomes Cancer 53:549-57. 2014
    ..2014 Wiley Periodicals, Inc...
  61. pmc Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Haematologica 97:1761-7. 2012
    ..We evaluated the impact of this disease feature on patients' outcome in the context of novel agents...
  62. ncbi request reprint Treatment advances in multiple myeloma
    Guido Tricot
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 125:24-30. 2004
  63. ncbi request reprint NY-ESO-1 immunotherapy for multiple myeloma
    Susann Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leuk Lymphoma 47:2037-48. 2006
    ..NY-ESO-1 based therapies are already being tested in clinical trials for a multitude of tumors. This review discusses the potential of NY-ESO-1 immunotherapy to improve outcome for myeloma...
  64. ncbi request reprint Predicting long-term survival in multiple myeloma patients following autotransplants
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AK 72205, USA
    Leuk Lymphoma 44:749-58. 2003
    ..Furthermore, patients with less favorable outcome should be identified early in their disease course and should be managed with novel and hopefully more effective treatments...
  65. ncbi request reprint Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Blood 99:1745-57. 2002
    ..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM...
  66. pmc Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Stem Cells 29:263-73. 2011
    ..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis...
  67. ncbi request reprint Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 20:1295-303. 2002
    ..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)...
  68. ncbi request reprint Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    Jeffrey Haessler
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 13:7073-9. 2007
    ..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
  69. doi request reprint Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
    ..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
  70. ncbi request reprint Allografting or autografting for myeloma
    Frits van Rhee
    N Engl J Med 356:2646-8; author reply 2646-8. 2007
  71. pmc High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
    Frits van Rhee
    Blood 110:827-32. 2007
    ..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival...
  72. ncbi request reprint CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
    Eric D Hsi
    Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Cancer Res 14:2775-84. 2008
    ....

Research Grants4

  1. Potentiating Natural Killer Cell Anti-Myeloma Effects
    Frits van Rhee; Fiscal Year: 2008
    ..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..
  2. Potentiating Natural Killer Cell Anti-Myeloma Effects
    Frits van Rhee; Fiscal Year: 2009
    ..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..
  3. Potentiating Natural Killer Cell Anti-Myeloma Effects
    Frits van Rhee; Fiscal Year: 2010
    ..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..
  4. Potentiating Natural Killer Cell Anti-Myeloma Effects
    Frits van Rhee; Fiscal Year: 2009
    ..This grant proposal describes 3 new ways in which the patient's own immune cells can be used to destroy the cancer. Such treatment may also be useful to treat other cancers. ..